All Stories

Jazz Pharma forks over $145M to shake off antitrust claims tied to narcolepsy drug Xyrem

The company settled with several purchaser plaintiffs in an antitrust case that involved Jazz and generic Xyrem maker Hikma Pharmaceuticals.

Apr 10, 2025 - 13:51
 0
Jazz Pharma forks over $145M to shake off antitrust claims tied to narcolepsy drug Xyrem
The company settled with several purchaser plaintiffs in an antitrust case that involved Jazz and generic Xyrem maker Hikma Pharmaceuticals.
Read More

Tags:

Previous Article

Denver developer to begin construction on historical Phoenix building

Next Article

Keros considers a sale, strengthens defense against potential activist investors

Related Posts

Novartis plots 427 layoffs in New Jersey as looming Entresto patent cliff sparks marketing refresh

Novartis plots 427 layoffs in New Jersey as looming Ent...

Mar 18, 2025  0

After peptide expansion, Axplora hits the gas to boost ADC capacity at French facility

After peptide expansion, Axplora hits the gas to boost ...

Mar 5, 2025  0

Argenx stays on a roll with Vyvgart, gaining FDA nod for at-home prefilled syringe

Argenx stays on a roll with Vyvgart, gaining FDA nod fo...

Apr 11, 2025  0